| Objective:Atorvastatin calcium dispersible tablets were given orally to patients with acute exacerbation of chronic obstructive pulmonary disease,and the changes of serum inflammatory markers(Tumor necrosis factor ? and c reactive protein)and pulmonary function were observed.To investigate whether atorvastatin affects systemic inflammation and pulmonary function in patients with AECOPD.Methods:A total of 80 patients with AECOPD and elevated margins of total cholesterol who were treated in the Department of Respiratory Medicine at the 921 Hospital of the People's Liberation Army Joint Service Support Force from December 2018 to September 2019 were selected.Requirements for these 80 patients: lung function level II,(FEV1/FVC<70% and 50%?FEV1%<80% after bronchodilator inhalation);and 5.18mmol/L ? TC <6.19mmol/L.The 80 patients were divided into two groups: the conventional treatment group(group B)and the atorvastatin intervention group(group A),with 40 patients in each group.In the same period,40 patients(5.18mmol/L ? TC <6.19mmol/L)were selected as the blank group(group C)for the first time in the clinic.Basic information such as age,blood lipids,gender,onset of illness,height and weight of all patients were recorded.Group B received conventional AECOPD treatment:anti-infective treatment(cefoperazone sodium tazobactam sodium 2g + 0.9% sodium chloride injection 100 ml,intravenous drip,2 days,given the same batch of drugs for 7 days);diastolic bronchial therapy(inhaled tiotropium bromide powder 18 ug,inhaled,1 / day,for 10 days;theophylline sustained-release tablets 0.1g,oral,2 / day,for 10 days);treatment of cough and expectoration;low flow oxygen therapy(oxygen inhalation with bilateral nasal cannula,2L / min,8 hours per day for 10 days).Group A: Add atorvastatin calcium dispersible tablet 10 mg orally once a night for 10 days on the basis of conventional COPD treatment.Group C is not treated as a blank group.Patients in groups A and B were taken venous blood on an empty stomach in the morning before receiving the treatment plan and 10 days after receiving the treatment plan.Group C subjects took venous blood in the morning on an empty stomach on the day of the physical examination.All specimens were sent to the biochemistry room of the Laboratory of our hospital.Serum TNF-? and CRP levels were measured by ELISA.Patients in groups A and B were examined for lung function before and 10 days after receiving treatment.Participants in group C were checked for lung function during the physical examination.Results:1.Before treatment,TNF-? and CRP levels in groups A and B were higher than those in group C,while FEV1 and FEV1% were significantly lower than those in group C,and these differences were statistically significant(P<0.01).There was no significant difference in TNF-?,CRP,FEV1,and FEV1% between the group A and B before treatment(P> 0.05).2.After treatment,the levels of serum TNF-? and CRP in the A and B groups were lower than before(P <0.01),and the group A had a more significant decrease than the group B(P <0.05).3.After treatment,FEV1 and FEV1% were improved in group A and group B(P<0.01).There was no statistically significant improvement between group A and group B(P>0.05).4.Serum TNF-? and CRP were negatively correlated with lung function FEV1 and FEV1%,and the differences were statistically significant(P <0.01).Conclusion:Inflammatory markers CRP and TNF-? were significantly increased in AECOPD patients.Atorvastatin can reduce serum CRP and TNF-? levels in AECOPD patients,which may play a role in reducing airway inflammation.But taking this medicine in the short term does not significantly improve lung function. |
PDF Full Text Request